Blood cancer illustrative concept
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial – in other words, for now, that patient is cancer-free.

This latest breakthrough – which could bode well for Chimeric shareholders, given the stock is currently suspended – comes on the back of a trial using a combination of ‘CORE-NK‘ and Vactosertib in advanced cancer patients.

‘CORE-NK’ takes its name from Natural Killer (NK) cells which “are part of our innate immune system,” according to the company’s website. A previous trial found more success combining it with Vactosertib.

This is the first round of trials to ever mix that drug with NK cell treatments; the trial is being undertaken at the UH Seidman Cancer Center in Ohio, USA.

“We are very happy to report that one study subject with advanced Acute Myelogenous Leukemia (AML) experienced a Complete Response at Day 28 after starting treatment with the CHM CORE- NK + Vactosertib combination,” Chimeric COO Dr. Rebecca McQualter said.

“As the study continues to enrol subjects with advanced cancer, we are pleased to see the clinical combination can be delivered safely.”

“The patient will continue on study and be monitored for up to 15 years, a standard FDA requirement for all cell therapy trials. Three patients are currently enrolled in the Phase 1b study with the goal to enrol 12 patients,” the company wrote on Monday.

CHM last traded at 1.4cps.

Join the discussion: See what HotCopper users are saying about Chimeric Therapeutics and be part of the conversations that move the markets.

CHM by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Miners drag bourse lower as Chinese stimulus disappoints | November 11, 2024

Investors reacted with disappointment to underwhelming Chinese stimulus measures released over the weekend.
The Market Online Video

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more…
The Market Online Video

ASX Market Update: Index retreats as Chinese stimulus disappoints | November 11, 2024

Investors reacted with disappointment to the latest Chinese stimulus measures released on the weekend.
Landscape in Finland

Prospech finds dynamite heavy REE grades from historic core in Finland

Prospech Ltd has found up to 86 ppm terbium and 313.4 ppm dysprosium at its Korsnäs…